Relationship Between Serum Fetuin B Level And Non-alcoholic Fatty Liver Diseases With Coronary Heart Disease

Background and Objective: It is well known that the liver is involved in the natural progression of the ongoing epidemics of cardiovascular disease.The liver plays an important role in increased glucose production and disordered lipoprotein metabolism,especially in non-alcoholic fatty liver diseases(NAFLD)patients.Currently,several proteins called hepatokines that are exclusively or primarily secreted from the liver are now known to directly affect glucose and lipid metabolism.Such proteins include Fetuin A,fibroblast growth factor 21(FGF21)and selenoprotein P,which are widely involved in the pathophysiological processes of insulin resistance(IR)and atherosclerosis,and are linked NAFLD to cardiovascular risk diseases.Fetuin B(Fetuin B)is the second member of the fetuin family and is currently considered to be a hepatokine,which is increased in humans with liver steatosis and affects metabolism through interactions with tissues.At present,there are significant differences in the studies on the metabolic diseases,such as obesity,NAFLD and coronary heart disease(CHD),and there is no research on the risk of serum Fetuin B and CHD in NAFLD population.The aim of this paper is to investigate the correlation between serum Fetuin B and CHD in patients with NAFLD.Methods:120 Patient with NAFLD were divided into two groups according to the coronary arteriography: 89 cases with CHD and 31 cases without.In the same period,17 individuals were served as controls.All the subjects were inpatients and outpatients of Qingdao Municipal Hospital.Height,weight,systolic blood pressure(SBP),diastolic blood pressure(DBP),fasting blood glucose(FPG),total cholesterol(TC),triglyceride(TG),high-density lipoprotein(HDL)and low density lipoprotein(LDL),albumin(Alb),alanine transaminase(ALT),glutamate transaminase(AST),gamma-glutamate transferase(GGT),uric acid(UA),creatinine(Scr)were determined in all persons.Calculate body mass index(BMI)and glomerular filtration rate(e GFR).TheLiver stiffness measurement(LSM)and controlled attenuation parameters(CAP)were determined by transient elastography(Fibro Scan)in 89 patients with CHD and NAFLD.The serum Fetuin B concentration of all subjects was determined by a two-antibody one-step sandwich immunosorbent assay(ELISA).Statistical analysis of all data was performed using SPSS20.0 statistical software.Normal distribution was detected in all measurement data.For the data that conforms to the normal distribution,One-Way ANOVA was used for comparison between the three groups,SNK test was used for the comparison between groups.;for data that did not meet the normal distribution,k independent samples test was used between the three groups,pairwise comparisons test was used for the comparison between groups.The two classification variables were analyzed by chi-square test.Correlation analysis was performed with Spearman correlation test.P<0.05 was considered statistically significant.Results: The serum Fetuin B level was significantly increased in the group of NAFLD with and without CHD than the group of controls[(670.3±191.4),(658.4±240.0)?g/ml vs(540.7±112.5)?g/ml],(P<0.05).However,there was no significant difference in serum Fetuin B in patients with and without CHD(P>0.05).Spearman correlation coefficient analysis showed that serum Fetuin B was positively correlated with TC and negatively correlated with GGT in controls(r=0.624,P=0.007;r=-0.576,P=0.015);it was positively correlated with BMI in patients with CHD(r=0.328,P=0.002).No correlation between serum Fetuin B and CAP and LSM was found.This suggests a potential link between Fetuin B and metabolic risk factors such as obesity and dyslipidemia.Conclusion: Serum Fetuin B may be involved in the pathogenesis of NAFLD through metabolic risk factors,such as obesity and dyslipidemia.There was no direct correlation between serum Fetuin B and NAFLD complicated by CHD.